We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Genetic Markers Predict Susceptibility of Pancreatic Tumors

By LabMedica International staff writers
Posted on 18 Mar 2019
A panel of genetic markers allows clinicians to match pancreatic tumors with appropriate existing chemotherapeutic drugs.

Since it has been difficult to select suitable treatment for patients with pancreatic ductal adenocarcinomas (PDACs) based on genomic alterations, investigators at the University of Pittsburgh (PA, USA), performed targeted genomic profile analyses of a large number of PDACs to evaluate the full spectrum of treatable genomic alterations.

Previously, these investigators had developed "PancreaSeq", a clinical molecular test to evaluate common pancreatic cysts and identify which cases may progress to cancer. More...
The assay targets mutation detection by next generation sequencing in pancreatic cyst fluid fine needle aspiration (FNA) specimens. The PancreaSeq panel offers simultaneous sequencing and detection of mutations in eight pancreatic cancer-related genes (AKT1, CTNNB1, GNAS, KRAS, PIK3CA, PTEN, TP53, and VHL).

For the current study, the investigators performed targeted genomic profile analyses of 3594 PDAC samples from an international cohort, including capture-based targeted genomic profiling of as many as 315 cancer-associated genes and intron regions of 28 genes that were rearranged in cancer cells. Tumor mutation burden (TMB) and microsatellite instability (MSI) status were also assessed.

Results revealed that KRAS, TP53, CDKN2A, and SMAD4 were the most frequently altered genes in the PDAC tissues. KRAS mutations were found in 88% of samples. Among PDACs without mutations in KRAS, alterations were found in genes whose products were in the mitogen-activated protein kinase signaling pathway and were candidate drug targets, as well as gene fusions, gene amplifications, genes with missense mutations, and genes that contained deletions. Many of these encoded proteins in receptor tyrosine kinase, RAS, or mitogen-activated protein kinase signaling pathways. A genetic marker, which indicated that the tumor should be susceptible to existing chemotherapy drugs, was found in 17% percent of cases.

“Every pancreatic cancer is different, and performing molecular profiling of each patient’s tumor could help determine the best treatment options,” said first author Dr. Aatur Singhi, assistant professor of pathology at the University of Pittsburgh. “Rather than blindly giving patients the same chemotherapy, we want to tailor a patient’s chemo to their tumor type. A one-size-fits-all approach is not going to work. Therefore, we would like to make molecular profiling standard-of-care for patients with pancreatic cancer.”

The study was published in the March 2, 2019, online edition of the journal Gastroenterology.

Related Links:
University of Pittsburgh


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
New
Nucleic Acid Purification Instrument
QIAsymphony Connect
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: Shutterstock

Blood Test Could Guide Drug Selection to Prevent Repeat Heart Attacks and Strokes

Secondary prevention after myocardial infarction or stroke relies on antiplatelet therapy, yet responses vary widely and both recurrent thrombosis and bleeding remain persistent risks. In the United Kingdom,... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Type 1 diabetes affects more than 9 million people worldwide and can begin years before symptoms appear, making early identification of at-risk children difficult (Image Credit: iStock)

Early-Life Gut Microbiome Changes May Help Assess Type 1 Diabetes Risk

Type 1 diabetes (T1D) affects more than 9 million people worldwide, including 1.8 million children and adolescents, and often begins years before symptoms appear. Early identification of children who are... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.